![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SIGLEC6 |
Gene summary for SIGLEC6 |
![]() |
Gene information | Species | Human | Gene symbol | SIGLEC6 | Gene ID | 946 |
Gene name | sialic acid binding Ig like lectin 6 | |
Gene Alias | CD327 | |
Cytomap | 19q13.41 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | O43699 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
946 | SIGLEC6 | HCC1 | Human | Liver | HCC | 1.89e-02 | 2.43e-01 | 0.5336 |
946 | SIGLEC6 | HCC2 | Human | Liver | HCC | 2.08e-08 | 1.76e+00 | 0.5341 |
946 | SIGLEC6 | HCC5 | Human | Liver | HCC | 1.75e-08 | 5.99e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SIGLEC6 | SNV | Missense_Mutation | novel | c.881N>T | p.Asn294Ile | p.N294I | O43699 | protein_coding | tolerated(0.23) | benign(0.246) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
SIGLEC6 | SNV | Missense_Mutation | c.279N>G | p.Phe93Leu | p.F93L | O43699 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SIGLEC6 | SNV | Missense_Mutation | c.896C>G | p.Ser299Cys | p.S299C | O43699 | protein_coding | tolerated(0.09) | possibly_damaging(0.569) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
SIGLEC6 | SNV | Missense_Mutation | rs752121580 | c.556N>T | p.Ala186Ser | p.A186S | O43699 | protein_coding | tolerated(0.58) | possibly_damaging(0.72) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SIGLEC6 | SNV | Missense_Mutation | novel | c.581N>A | p.Thr194Asn | p.T194N | O43699 | protein_coding | tolerated(0.08) | possibly_damaging(0.55) | TCGA-BH-A8FY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SIGLEC6 | SNV | Missense_Mutation | novel | c.1270C>A | p.Leu424Ile | p.L424I | O43699 | protein_coding | tolerated(0.33) | benign(0.232) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
SIGLEC6 | deletion | Frame_Shift_Del | novel | c.950delN | p.Phe317SerfsTer16 | p.F317Sfs*16 | O43699 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
SIGLEC6 | SNV | Missense_Mutation | c.103G>A | p.Gly35Arg | p.G35R | O43699 | protein_coding | deleterious(0) | benign(0.034) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
SIGLEC6 | SNV | Missense_Mutation | novel | c.973N>G | p.Leu325Val | p.L325V | O43699 | protein_coding | tolerated(0.08) | possibly_damaging(0.733) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SIGLEC6 | insertion | Frame_Shift_Ins | novel | c.530_531insAGGT | p.Pro178GlyfsTer99 | p.P178Gfs*99 | O43699 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |